Clinical Trials · NCT00569127
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 427
- Start date
- Dec 2007
- Locations
- 493 sites, United States
- Primary endpoint
- Central Review-based Progression-Free Survival